WATERTOWN, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the company will present at the following upcoming conferences:
- Craig Thompson, Chief Operating Officer, will present at the 2015 BIO International Convention on Thursday, June 18th at 11:15 a.m. Eastern Time at the Pennsylvania Convention Center in Philadelphia, PA
- Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23rd at 3:00 p.m. Eastern Time at The St. Regis in New York City.
A live audio webcast of the JMP presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, a broad-spectrum intravenous and oral antibiotic that is being evaluated in phase 3 clinical trials, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 email@example.com Argot Partners Susan Kim 212-600-1902 firstname.lastname@example.org Media Contact: Sam Brown Inc. Mariesa Kemble 608-850-4745 email@example.com